[go: up one dir, main page]

ME02730B - Modulatori enzima koji modifikuju metil, njihove kompozicije i upotreba - Google Patents

Modulatori enzima koji modifikuju metil, njihove kompozicije i upotreba

Info

Publication number
ME02730B
ME02730B MEP-2017-141A MEP2017141A ME02730B ME 02730 B ME02730 B ME 02730B ME P2017141 A MEP2017141 A ME P2017141A ME 02730 B ME02730 B ME 02730B
Authority
ME
Montenegro
Prior art keywords
modulators
compositions
modifying enzymes
methyl modifying
methyl
Prior art date
Application number
MEP-2017-141A
Other languages
German (de)
English (en)
French (fr)
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50239937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02730(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/025639 external-priority patent/WO2013120104A2/en
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of ME02730B publication Critical patent/ME02730B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MEP-2017-141A 2013-02-11 2014-02-11 Modulatori enzima koji modifikuju metil, njihove kompozicije i upotreba ME02730B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2013/025639 WO2013120104A2 (en) 2012-02-10 2013-02-11 Modulators of methyl modifying enzymes, compositions and uses thereof
EP14708987.4A EP2953941B1 (en) 2013-02-11 2014-02-11 Modulators of methyl modifying enzymes, compositions and uses thereof
PCT/US2014/015706 WO2014124418A1 (en) 2013-02-11 2014-02-11 Modulators of methyl modifying enzymes, compositions and uses thereof

Publications (1)

Publication Number Publication Date
ME02730B true ME02730B (me) 2017-10-20

Family

ID=50239937

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-141A ME02730B (me) 2013-02-11 2014-02-11 Modulatori enzima koji modifikuju metil, njihove kompozicije i upotreba

Country Status (17)

Country Link
EP (1) EP2953941B1 (me)
KR (1) KR102219441B1 (me)
CN (1) CN105102446B (me)
CL (1) CL2015002239A1 (me)
CR (1) CR20150457A (me)
HK (1) HK1218648A1 (me)
IL (1) IL239985B (me)
MA (1) MA38341B1 (me)
ME (1) ME02730B (me)
PE (1) PE20160044A1 (me)
PH (1) PH12015501720A1 (me)
PL (1) PL2953941T3 (me)
RS (1) RS56207B1 (me)
SG (1) SG11201506077XA (me)
SI (1) SI2953941T1 (me)
TW (1) TWI629273B (me)
WO (1) WO2014124418A1 (me)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
MY186837A (en) 2014-12-23 2021-08-25 Novartis Ag Triazolopyrimidine compounds and uses thereof
US20180037568A1 (en) * 2015-02-13 2018-02-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2017018975A1 (en) 2015-07-24 2017-02-02 Constellation Pharmaceuticals, Inc. Combination therapies for modulation of histone methyl modifying enzymes
AU2016302747A1 (en) * 2015-08-03 2018-02-22 Constellation Pharmaceuticals, Inc. EZH2 inhibitors and modulation of regulatory T-cell function
EA201890567A1 (ru) 2015-08-24 2018-08-31 Эпизайм, Инк. Способ лечения рака
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
EP3371175A4 (en) 2015-10-06 2019-09-25 Epizyme Inc METHOD FOR THE TREATMENT OF MEDULLOBLASTOMY WITH AN EZH2 INHIBITOR
EP3371601A1 (en) 2015-11-05 2018-09-12 Epizyme Inc Flow cytometry for monitoring histone h3 methylation status
CA3011186A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
CN105669647B (zh) * 2016-02-22 2018-05-04 上海皓元生物医药科技有限公司 一种组蛋白甲基化酶ezh2抑制剂中间体的合成方法
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
WO2017221092A1 (en) 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
IL263429B (en) 2016-06-20 2022-08-01 Novartis Ag Crystalline forms of triazolopyrimidine compound
CN109790166A (zh) * 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
EP3548032A2 (en) 2016-12-02 2019-10-09 Epizyme, Inc. Combination therapy for treating cancer
KR20190105602A (ko) 2017-01-19 2019-09-17 다이이찌 산쿄 가부시키가이샤 Htlv-1 관련 척수증을 치료하는 것에 사용하기 위한 의약 조성물
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
WO2018231973A1 (en) 2017-06-13 2018-12-20 Epizyme, Inc. Inhibitors of ezh2 and methods of use thereof
US20210161883A1 (en) 2017-07-10 2021-06-03 Constellation Pharmaceuticals, Inc. Ezh2 inhibitor-induced gene expression
EP3707136B1 (en) * 2017-11-09 2022-05-04 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JP7201400B2 (ja) 2017-11-14 2023-01-10 ファイザー・インク Ｅｚｈ２阻害剤組合せ療法
CN109879790B (zh) * 2017-12-06 2022-09-20 华东师范大学 以吲哚或吲哚类似物为母核结构的酰胺类小分子有机化合物、用途及其制备方法
EP3731842A1 (en) 2017-12-28 2020-11-04 Constellation Pharmaceuticals, Inc. Pharmacokinetic enhancement of ezh2 inhibitors through combination therapies
PT4043466T (pt) 2018-01-31 2024-10-14 Mirati Therapeutics Inc Inibidores de prc2
CN110229157B (zh) * 2018-03-06 2022-06-21 上海海和药物研究开发股份有限公司 嘧啶并五元芳香杂环类化合物、其制备方法及用途
CN110229151B (zh) * 2018-03-06 2021-09-10 上海海和药物研究开发股份有限公司 吲嗪类化合物、其制备方法及用途
MX2020009530A (es) 2018-03-14 2021-01-15 Biogen Ma Inc Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN112399857A (zh) 2018-07-09 2021-02-23 盲人庇护基金会 Prc2亚单位的抑制治疗眼失调
AU2019344922B2 (en) 2018-09-19 2025-02-06 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
ES2968733T3 (es) 2018-12-05 2024-05-13 Biogen Ma Inc Derivados morfolinilo, piperazinilo, oxazepanilo y diazepanilo útiles como inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
WO2020139339A1 (en) 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
UY38567A (es) 2019-02-04 2020-08-31 Biogen Ma Inc Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico
EP3935055A1 (en) 2019-03-08 2022-01-12 Biogen MA Inc. Azetidinyl 0-glyc0pr0tein-2-acetamid0-2-deoxy-3-d-gluc0pyran0sidase inhibitors
EP4003343A1 (en) 2019-07-24 2022-06-01 Constellation Pharmaceuticals, Inc. Ezh2 inhibition in combination therapies for the treatment of cancers
PH12022550188A1 (en) * 2019-07-24 2022-11-21 Constellation Pharmaceuticals Inc Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
UY38934A (es) 2019-10-29 2021-05-31 Biogen Ma Inc Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica
KR20230061395A (ko) 2020-08-03 2023-05-08 바이오젠 엠에이 인코포레이티드 O-당단백질-2-아세트아미도-2-데옥시-3-d-글루코피라노시다제 억제제의 결정질 형태
CN112679505B (zh) * 2020-12-25 2022-04-22 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
WO2022150962A1 (en) 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
US20250049802A1 (en) 2021-12-14 2025-02-13 Pfizer Inc. Combination therapies and uses for treating cancer
CN119095624A (zh) 2022-04-27 2024-12-06 第一三共株式会社 抗体-药物缀合物与ezh1和/或ezh2抑制剂的组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2566327T (lt) * 2010-05-07 2017-05-25 Glaxosmithkline Llc Indolai
EP2681216B1 (en) * 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2812001B1 (en) * 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Also Published As

Publication number Publication date
CN105102446B (zh) 2018-01-23
RS56207B1 (sr) 2017-11-30
SI2953941T1 (sl) 2017-08-31
SG11201506077XA (en) 2015-08-28
PH12015501720B1 (en) 2015-11-09
IL239985A0 (en) 2015-09-24
KR20150119201A (ko) 2015-10-23
EP2953941A1 (en) 2015-12-16
CL2015002239A1 (es) 2016-02-05
CR20150457A (es) 2015-10-20
HK1218648A1 (zh) 2017-03-03
KR102219441B1 (ko) 2021-02-23
PL2953941T3 (pl) 2017-11-30
MA38341A1 (fr) 2018-01-31
CN105102446A (zh) 2015-11-25
PE20160044A1 (es) 2016-02-11
IL239985B (en) 2018-11-29
MA38341B1 (fr) 2018-11-30
PH12015501720A1 (en) 2015-11-09
EP2953941B1 (en) 2017-04-05
TW201443038A (zh) 2014-11-16
TWI629273B (zh) 2018-07-11
WO2014124418A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
HK1218648A1 (zh) 甲基修飾酶的調節劑、其組合物及用途
LT2953941T (lt) Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas
IL244081A0 (en) Preparations and methods for modulating RNA
IL265876A (en) Preparations that include 15-ohepa and methods of using them
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
EP2992097A4 (en) Compositions and methods
EP2951283A4 (en) Compositions and methods
EP3071588A4 (en) Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto
EP3039131A4 (en) Enzyme composition and uses thereof
EP3038634A4 (en) Novel sez6 modulators and methods of use
EP3075097A4 (en) Construction and uses of variable-input-length tweakable ciphers
EP2983681A4 (en) Therapeutic compositions and uses thereof
EP2992334A4 (en) Novel phosphatidylalkanols and compositions thereof
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
EP3087056A4 (en) Glucocerebrosidase modulators and uses thereof
SG11201505891VA (en) Catalyst compositions and methods of making and using same
HK1223632A1 (zh) 靶向的酶化合物及其用途
EP2943575A4 (en) COMPOSITIONS AND METHODS FOR PRODUCING ENZYMES
GB201309178D0 (en) Enzyme and uses thereof
EP3043780A4 (en) Novel delivery compositions and methods of using same
HK1216891A1 (zh) 苔蘚素組合物、其製備方法和用途
HK1217670A1 (zh) 調配物、其製造方法和用途
EP3052051A4 (en) STABILIZED ENZYME COMPOSITIONS
AU2013902874A0 (en) Compositions and methods
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same